IGM Biosciences Inc (IGMS)
9.43
-0.05
(-0.53%)
USD |
NASDAQ |
May 02, 16:00
9.38
-0.05
(-0.53%)
After-Hours: 20:00
IGM Biosciences Research and Development Expense (Quarterly): 54.19M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 54.19M |
| September 30, 2023 | 54.76M |
| June 30, 2023 | 55.67M |
| March 31, 2023 | 50.89M |
| December 31, 2022 | 45.02M |
| September 30, 2022 | 48.18M |
| June 30, 2022 | 47.22M |
| March 31, 2022 | 38.88M |
| December 31, 2021 | 39.17M |
| September 30, 2021 | 34.20M |
| June 30, 2021 | 30.09M |
| Date | Value |
|---|---|
| March 31, 2021 | 23.57M |
| December 31, 2020 | 19.60M |
| September 30, 2020 | 15.83M |
| June 30, 2020 | 15.02M |
| March 31, 2020 | 14.58M |
| December 31, 2019 | 12.76M |
| September 30, 2019 | 8.279M |
| June 30, 2019 | 8.303M |
| March 31, 2019 | 5.912M |
| December 31, 2018 | 7.814M |
| September 30, 2018 | 5.172M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.279M
Minimum
Sep 2019
55.67M
Maximum
Jun 2023
32.43M
Average
34.20M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Inotiv Inc | -- |
| Synlogic Inc | 10.14M |
| BioXcel Therapeutics Inc | 9.934M |
| Xilio Therapeutics Inc | 11.74M |
| NovaBay Pharmaceuticals Inc | 0.004M |